Biodexa Pharmaceuticals Plc Files 6-K Report
Ticker: BDRX · Form: 6-K · Filed: Jul 16, 2024 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Jul 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, pharmaceuticals
TL;DR
Biodexa Pharma (BDRX) filed a standard 6-K update with the SEC on 7/16.
AI Summary
Biodexa Pharmaceuticals Plc, formerly Midatech Pharma Plc, filed a Form 6-K on July 16, 2024. The filing indicates that the company, based in Cardiff, United Kingdom, operates in the Pharmaceutical Preparations sector. This report is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Why It Matters
This filing is a routine report for foreign private issuers, providing updates to the SEC and investors about the company's ongoing activities and compliance.
Risk Assessment
Risk Level: low — This filing is a routine administrative report and does not contain significant new financial or operational information that would typically increase risk.
Key Numbers
- 001-37652 — SEC File Number (Identifies the specific SEC filing for Biodexa Pharmaceuticals Plc)
- 20240716 — Filing Date (Date the Form 6-K was filed with the SEC)
Key Players & Entities
- Biodexa Pharmaceuticals Plc (company) — Filer of the 6-K report
- Midatech Pharma Plc (company) — Former name of Biodexa Pharmaceuticals Plc
- United States Securities and Exchange Commission (company) — Recipient of the filing
- 2834 (dollar_amount) — Standard Industrial Classification code for Pharmaceutical Preparations
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information that the company makes or is required to make public in its home country.
What was Biodexa Pharmaceuticals Plc's former name?
Biodexa Pharmaceuticals Plc was formerly known as Midatech Pharma Plc, with a date of name change on June 2, 2015.
Where is Biodexa Pharmaceuticals Plc located?
Biodexa Pharmaceuticals Plc is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
What is Biodexa Pharmaceuticals Plc's Standard Industrial Classification (SIC) code?
Biodexa Pharmaceuticals Plc's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Does this filing incorporate information by reference into other filings?
The filing states that the information in Exhibit 99.1 is being furnished and shall not be deemed 'filed' for the purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing made by the company.
Filing Stats: 264 words · 1 min read · ~1 pages · Grade level 15.2 · Accepted 2024-07-16 08:46:42
Filing Documents
- f6k_071624.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 8KB
- 0001171843-24-003967.txt ( ) — 15KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC (Registrant) Date: July 16, 2024 /s/ Stephen Stamp Stephen Stamp Chief Executive Officer, Chief Financial Officer